US OptionsDetailed Quotes
CDTX241220C7500
- 0.00
- 0.000.00%
15min DelayClose Dec 13 09:30 ET
0.00High0.00Low
0.00Open0.00Pre Close0 Volume0 Open Interest7.50Strike Price0.00Turnover0.00%IV-67.22%PremiumDec 20, 2024Expiry Date15.38Intrinsic Value100Multiplier5DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type--Delta--Gamma--Leverage Ratio--Theta--Rho--Eff Leverage--Vega
Cidara Therapeutics Stock Discussion
RBC Capital Initiates Coverage On Cidara Therapeutics with Outperform Rating, Announces Price Target of $34
Cidara Therapeutics | SC 13G: Statement of acquisition of beneficial ownership by individuals-TCG Crossover GP II, LLC(9.2%),TCG Crossover Fund II, L.P.(9.2%), etc.
1. Not all of these stocks will go up. Everything relies on market sentiment/buy pressure, the satanic shorts including dark pool.
2. The SI CTB and shorts availability are based on 11/29 data and may get updated Monday.
3. NEVER open position without momentum.
4. If you are expecting all stocks to be a runner,then you are set for failure, losses, and bagholding. Not all good news run and not all bad news crash the pri...
Cidara Therapeutics | SC 13D/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-RA Capital Management, L.P.(9.99%),Peter Kolchinsky(9.99%), etc.
Cash available will sustain the operations for 24 months (exclude 105mil private placement). Upcoming catalyst September 2025.
No comment yet